2 days Ago By ABMN Staff
Repligen Co. ( NASDAQ:RGEN – Get Free Report ) has earned an average rating of “Moderate Buy” from the eleven analysts that are currently covering the company, MarketBeat Ratings reports. Three analysts have rated the stock with a hold rating and eight have given a buy rating to the company.
The average twelve-month price target among brokerages that have issued ratings on the stock in the last year is $190.25. A number of analysts recently weighed in on the company.
JPMorgan Chase & Co. boosted their target price on Repligen from $190.00 to $200.
00 and gave the stock an “overweight” rating in a research report on Wednesday, July 31st. Wells Fargo & Company began coverage on shares of Repligen in a report on Tuesday, August 27th. They issued an “overweight” rating and a $180.
00 price objective for the company. Wolfe Research began coverage on shares of Repligen in a research report on Thursday, November 14th. They issued a “peer perform” rating on the stock.
StockNews.com upgraded shares of Repligen from a “sell” rating to a “hold” rating in a research report on Friday. Finally, Stephens reiterated an “overweight” rating and issued a $170.
00 price objective on shares of Repligen in a report on Tuesday, July 30th. Get Our Latest Stock Analysis on Repligen Insider Buying and Selling at Repligen Institutional Investors Weigh In On Repligen Institutional investors and hedge funds have recently modified their holdings of the stock. Andra AP fonden bought a new stake in shares of Repligen during the second quarter valued at approximately $25,000.
Lazard Asset Management LLC boosted its holdings in shares of Repligen by 206.1% during the 1st quarter. Lazard Asset Management LLC now owns 202 shares of the biotechnology company’s stock valued at $36,000 after buying an additional 136 shares in the last quarter.
UMB Bank n.a. boosted its holdings in shares of Repligen by 138.
3% during the 3rd quarter. UMB Bank n.a.
now owns 224 shares of the biotechnology company’s stock valued at $33,000 after buying an additional 130 shares in the last quarter. Blue Trust Inc. grew its position in shares of Repligen by 113.
4% in the 3rd quarter. Blue Trust Inc. now owns 239 shares of the biotechnology company’s stock worth $36,000 after buying an additional 127 shares during the period.
Finally, Resources Management Corp CT ADV bought a new position in shares of Repligen in the 3rd quarter worth about $37,000. 97.64% of the stock is owned by hedge funds and other institutional investors.
Repligen Price Performance Shares of NASDAQ:RGEN opened at $142.58 on Friday. Repligen has a one year low of $113.
50 and a one year high of $211.13. The company has a debt-to-equity ratio of 0.
26, a current ratio of 10.44 and a quick ratio of 5.56.
The firm has a market capitalization of $7.99 billion, a price-to-earnings ratio of -385.34, a PEG ratio of 3.
87 and a beta of 0.96. The company’s fifty day moving average price is $140.
20 and its 200-day moving average price is $143.62. Repligen ( NASDAQ:RGEN – Get Free Report ) last released its earnings results on Tuesday, November 12th.
The biotechnology company reported $0.43 EPS for the quarter, beating analysts’ consensus estimates of $0.34 by $0.
09. Repligen had a positive return on equity of 3.90% and a negative net margin of 3.
36%. The business had revenue of $154.87 million for the quarter, compared to analysts’ expectations of $153.
34 million. During the same quarter in the prior year, the firm earned $0.23 earnings per share.
The firm’s revenue was up 9.7% on a year-over-year basis. On average, equities research analysts anticipate that Repligen will post 1.
52 earnings per share for the current fiscal year. Repligen Company Profile ( Get Free Report Repligen Corporation develops and commercializes bioprocessing technologies and systems for use in biological drug manufacturing process in North America, Europe, the Asia Pacific, and internationally. It offers Protein A ligands that are the binding components of Protein A affinity chromatography resins; and cell culture growth factor products.
See Also Receive News & Ratings for Repligen Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Repligen and related companies with MarketBeat.com's FREE daily email newsletter ..
